ARTICLE | Clinical News
AC2993 LAR: Phase I data; Phase II
August 20, 2001 7:00 AM UTC
AMLN reported that in a European Phase I study of multiple long-acting release formulations of AC2993 in 38 healthy volunteers, the product was well tolerated and sustained plasma concentrations of 30...